We have previously shown that activated C1s complement and activated T cells cleave β 2 -microglobulin (β 2 m) in vitro leading to the formation of desLys 58 β 2 m. This process can specifically be inhibited by C1-esterase inhibitor (C1-inh). Furthermore we showed that exogenously added desLys 58 β 2 m in nanomolar amounts to a one-way allogenic mixed lymphocyte culture (MLC) increased the endogenous production of IL-2 and the generation of allo-specific cytotoxic T lymphocytes. C1-inh was purified from fresh human plasma and added to human or murine MLC and mitogen-stimulated lymphocyte cultures grown in the presence of complement-inactivated serum. Read-outs were cell proliferation, lymphokine production and development of T cellmediated cytotoxicity. We found that addition of C1-inh to MLC and mitogen-exposed murine and human lymphocyte cultures inhibited proliferation, the development of allospecific cytotoxic activity, and changed the endogenous production of IL-2, IL-4, IL-10, IL-12 and IFN-γ. These data clearly demonstrate a regulatory function of C1-inh on T cell-mediated immune functions.
Introduction
The complement system is known to be of major importance in the defence against viral, bacterial and fungal infections. Through its interaction with antigen-antibody complexes, the complement system undergoes activation via the classical or via the alternative pathway by binding to carbohydrate structures on the surface of pathogens. This in turn leads to cell lysis of the invaders. Whereas much attention has been focused on the interactions between the complement system and the humoral immune system, only limited attention has been paid to the interaction between the complement system and the cellular immune responses.
In previous studies we have demonstrated that C1s complement specifically cleaves β 2 -microglobulin (β 2 m) C-terminal to Lys58. Subsequently, the C-terminal Lys58 residue is removed by a carboxypeptidase B-like activity present in serum leading to the formation of desLys 58 β 2 m (1,2). When added to a one-way allogeneic mixed lymphocyte culture (MLC) in nanomolar concentrations, desLys 58 β 2 m augments the endogenous production of IL-2 and the specific cytotoxic activity generated. Moreover, the responder cells of the MLC Correspondence to: M. H. Nissen
Transmitting editor: K. Eichmann Received 9 June 1997, accepted 24 October 1997 were found to cleave exogenously added β 2 m leading to formation of desLys 58 β 2 m (3). The present work is based on the following observations: (i) the proteolytic cleavage of β 2 m is caused specifically by C1s complement and can occur on the surface of activated T lymphocytes (3), (ii) C1-esterase inhibitor (C1-inh) is the only known inhibitor of this process (4, 5) , (iii) C1-inh has been found to be present on the cell surface of both normal and malignant cells (6) (7) (8) (9) , and (iv) complement factors are produced in mixed lymphocyte/macrophage cultures (10) . We have examined T cell functions of activated murine and human T cell cultures to which C1-inh was added in titrated, physiological doses in order to block specifically the proteolytic activity of endogenously produced C1s complement.
Methods

Animals and cells
BALB/c and C57BL/6 mice, 6-8 weeks old, were purchased from Gl. Bomholdtgaard (Aarhus, Denmark). Spleen cells were obtained by standard procedures. Human peripheral blood mononuclear cells were obtained from healthy donors by gradient centrifugation on Lymphoprep (Nygaard, Oslo, Norway) at 1200 g for 30 min. The cells were washed 3 times in RPMI medium and then quantified in a hemocytometer chamber.
Chemicals
Sephadex G-25, Sephadex G-150, DEAE A-50-Sephadex, lysine-Sepharose CL-4B and concanavalin A-Sepharose were obtained from Pharmacia Fine Chemicals (Uppsala, Sweden). Hydroxylapatite Bio-Gel HTP was obtained from BioRad (Hercules, CA). Na 2 SO 4 , benzamidine, KCl, citrate and concanavalin A type IV were obtained from Sigma (St Louis, MO). Phytohemagglutinin (PHA-P) was obtained from MEDA (Copenhagen, Denmark). EDTA was obtained from Merck (Darmstad, Germany). FCS was obtained from Gibco/ Biocult (Paisley, UK). Human AB serum was obtained from healthy individuals and found negative for cytotoxic antibodies. Serum was heat (complement)-inactivated at 56°C for 20 min prior to use.
Enzyme inhibitors
Trypsin inhibitor type II-L (T9378), trypsin inhibitor type II-T (T4385), trypsin inhibitor type I-S from soyabean (T9003), trypsin inhibitor type IV-O (T1886), trypsin inhibitor type III-O (T2011) and kallekrein (K3627) were purchased from Sigma. Trasylol (Aprotinin) was obtained from Bayer (Leverkusen, Germany). C1s was produced in our laboratory as previously described (1) .The inhibitor 4-chloro-3-(3-isothiureidopropoxy)isocoumarin was kindly provided by J. C. Powers (Georgia Institute of Technology, Atlanta, GA).
Purification of C1-inh C1-inh was purified from fresh human plasma according to the method described by Harrison (11) and modified by Davis et al. (12) . Briefly, 1200 ml of frozen plasma was thawed at 37°C followed by addition of EDTA and benzamidine to a final concentration of 5 mM each. Na 2 SO 4 was subsequently added to a final concentration of 10 g/100 ml at room temperature and stirred for 1-2 h. Precipitated protein was removed by centrifugation at 10,000 g for 30 min. The supernatant was then applied on a lysine-Sepharose CL-4B column equlibrated with 0.1 M potassium phosphate/0.5 M KCl/10 mM EDTA/5 mM benzamidine, pH 7.0. After application of the sample the column was washed with equlibration buffer until the A 280 of the eluate was zero. The eluate from the lysine-Sepharose column was then applied to a DEAESephadex A-50 column equlibrated with 20 mM phosphate buffer/0.1 M NaCl/5 mM EDTA/5 mM benzamidine, pH 7. Fractions containing C1-inh were identified by Ouchterlony immunodiffusion by using rabbit anti-human C1-inh antibody (Dakopatts, Copenhagen, Denmark). The fractions were then concentrated in an Amicon ultrafiltration cell using a XM50 membrane until a volume of 50 ml. The sample was then applied on a Sephadex G-150 Superfine column, equlibrated with 20 mM phosphate/0.1 M KCl/2 mM benzamidine/2 mM citrate, pH 7.0. C1-inh-containing fractions were identified by Ouchterlony immunodiffusion using rabbit anti-human C1-inh antibody. Fractions containing C1-inh were then dialyzed against 20 mM phosphate/150 mM KCl, pH 7.0, concentrated to 20 ml and applied on a hydroxylapatite column equlibrated with the same buffer. The C1-inh-containing fractions were identified by SDS-PAGE, pooled and concentrated to 7.5-10 mg/ml with Amicon ultrafiltration on an XM50 membrane. Finally the protein was transferred into a physiological phosphate buffer by Sephadex G-25 gel filtration. The purified protein was then stored in physiological PBS at -20°C until use. The purity of the protein was verified by SDS-PAGE and found to display only a single protein band with Coomassie brilliant blue and silver staining (see Fig. 1 ). The functional activity of purified C1-inh was determined according to Sim and Reboul (5) in the presence of activated C1s by using the chromogenic substrate N-carbobenzoxy-L-lysine-p-nitrophenyl ester (ZNLE) from Sigma or in the presence of S-2314
dihydrochloride; KabiVitrum, Stockholm, Sweden) as described by Berg et al. (13) . Alternatively inhibition of C1r complement-mediated cleavage of zymogen C1s complement or C1s-mediated cleavage of β 2 m was assayed. The C1-inh was added to the cultures in doses of 25-400 µg/ml in volumes of 20 µl per 200 µl well microcultures (see below). Alternatively C1-inh was purified by the method of Sim and Reboul (5) as described previously by us (1) using concanavalin A-Sepharose. The results using C1-inh by the two purification methods was identical. In the present study, only C1-inh purified by the method of Harrison (11) 
Cytotoxicity assay
At the end of the 5 day incubation period of the murine MLC, aliquots of 100 µl culture medium were replaced with 5000 c.p.m. 51 Cr-labeled EL4 (H-2 b ) target cells (ATCC, Rockville, MD) in 100 µl. For labeling, 2ϫ10 6 EL4 cells were incubated for 1 h at 37°C in 150 µl Na 51 chromate (100 µCi) containing 30% FCS followed by four washings. After 4 h of incubation, aliquots of 100 µl culture medium were transferred to test tubes for γ counting. Spontaneous and total 51 Cr release were determined from cultures containing 5ϫ10 5 irradiated stimulator cells and 3% acetic acid respectively. Percent specific chromium release was calculated according to the formula: 100ϫ[(experimental release -spontaneous release)/ (total release -spontaneous release)].
The source of IL-2 used in cytotoxicity assay was recombinant murine IL-2 (PharMingen, San Diego, CA). In separate experiments MLC were supplemented with 100 U/200 µl.
Proliferation assays
The period of culture was 2-5 days and 0.5 µCi/well [ 3 H]thymidine was present during the last 6 h of incubation. The cells were harvested on filter paper using an automatic cell harvester (Skatron, Bergen, Norway) and incorporated radioactivity determined by liquid scintillation counting.
Mitogen activation
Murine spleen cells, 3ϫ10 5 /well, or human peripheral blood mononuclear cells, 5ϫ10 4 /well, in replicates of four in a 96-well microculture tray, were cultured with mitogens: 40 µg/ml PHA or 5 µg/ml concanavalin A in the presence or absence of C1-inh for 3-5 days. [ 3 H]Thymidine (0.5 µCi/well) was added 6 h for murine cells and 24 h for human cells prior to harvest.
ELISA measurements of cytokines
The cytokines were all analyzed by sandwich ELISA using the manufacturer's protocols (PharMingen). For determination of cytokines by sandwich ELISA, the antibodies for coating the plates and the biotinylated secondary mAb were as follows: for IL-2, rat mAb anti-mouse IL-2 (JES6-1A12) and biotinylated mAb anti-mouse IL-2 (JES6-5H4); for IL-4, rat mAb anti-mouse IL-4 (11B11) and biotinylated mAb antimouse IL-4 (BVD6-24G2); for IL-10, rat mAb anti-mouse IL-10 (JES5-2A5) and biotinylated mAb anti-mouse IL-10 (SXC-1); for IL-12 p40/p70 , rat mAb anti-mouse IL-12 p40/p70 (C15.6) and biotinylated mAb anti-mouse IL-12 p40/p70 (C17.8); for IFN-γ, rat mAb anti-mouse IFN-γ (R4-6A2) and biotinylated mAb anti-mouse IFN-γ (XMG1.2); all obtained from PharMingen.
Detection of intracellular cytokines
The following mAb were used for detection of surface markers and intracellular cytokines. FITC-conjugated rat anti-mouse CD4 mAb (clone H129.19, IgG2a), FITC-conjugated rat antimouse CD8 mAb (clone 53-6.7, IgG2a), phycoerythrin (PE)-conjugated rat anti-mouse IL-2 mAb (clone S4B6, IgG2a), PE-conjugated rat anti-mouse IL-4 mAb (clone 11B11, IgG1), PE-conjugated rat anti-mouse IL-10 mAb (clone JES5-16E3, IgG2b), PE-conjugated rat anti-mouse IFN-γ mAb (clone XMG1.2, IgG1), FITC-conjugated rat IgG1/IgG2a negative control mAb (clone G28-5) and PE-conjugated rat IgG2a-negative control mAb (clone R35-95) were all purchased at PharMingen.
For the measurement of intracellular cytokines, freshly harvested MLC responder cells were washed twice, and stimulated for 4 h in the presence of 50 mM phorbol myristate acetate (Sigma) and 250 mM ionomycin (Sigma). To block exocytosis, 12 µM Monensin (Sigma) was added for the last 2 h. Following stimulation the cells were harvested and washed twice in PBS/2% FCS. The cells were stained for CD4 or CD8 expression for 30 min on ice. Subsequently, the cells were washed twice and fixed for 20 min in 4% paraformaldehyde at 4°C. Next, the cells were resuspended in 2 ml of PBS/0.2% saponin (Sigma) and left for 5 min at 4°C. Finally, the cells were resuspended in 30 µl PBS/saponin and incubated with saturating amounts of anti-cytokine mAb for 30 min at 4°C. Following the incubation the cells were washed twice in PBS/ 0.2% saponin. The samples were analyzed immediately using a FACScalibur flow cytometer (Becton Dickinson). Data were analyzed using CellQuest software (Becton Dickinson). The specificity of the anti-cytokine mAb was confirmed by using isotype mAb and by negative staining of non-permeabilized cells (data not shown).
Results
SDS-PAGE analysis
As shown in Fig. 1 analysis of C1-inh by SDS-PAGE demonstrates the purity of the protein both in Coomassie brilliant blue and silver staining. A minor band below the C1-inh is a degradation product of the C1-inh as detected by immunoblotting with C1-inh-specific antibodies.
C1-inh and other macromolecular protease inhibitors interfere with the proliferative response in the MLC C1-inh and a number of other protease inhibitors inhibit the proliferative response in a one-way murine MLC (Fig. 2) . The effect was not restricted to the murine system. Inhibition of a human MLC by C1-inh was also observed (Table 2) , as well as inhibition of lectin-induced proliferation in both the human and murine system (Table 1 and 2). Inhibition of the proliferative response in MLC was observed after addition of macromolecular trypsin inhibitors: turkey egg white trypsin inhibitor and chicken egg white trypsin inhibitor (ovoinhibitor) as shown in Fig. 2(B) , whereas soyabean trypsin inhibitor type I-S, trypsin inhibitor type IV-O, trypsin inhibitor type III-O and Trasylol (Aprotinin) did not cause inhibition of the proliferative response (data not shown). In addition, the synthetic C1 complement specific inhibitor 4-chloro-3-(3-isothiureidopropoxy)isocoumarin (14) was found to induce significant inhibition of the proliferative response in MLC as shown in Fig. 2(C) .
To exclude that the inhibition observed by C1-inh was caused by co-purification of a 'contaminating' substance, we purified the protein by two different methods (see Methods). C1-inh obtained by the two methods of purification displayed an identical inhibitory activity (data not shown). To further establish that the inhibitory activity was caused by C1-inh, a number of proteases with restricted substrate specificity such as C1s and kallikrein, known specifically to be inhibited by C1-inh, were added to the MLC in order to counteract the activity of C1-inh. As shown in Fig. 2(A) , the effect of C1-inh was abrogated in the presence kallikrein.
C1-inhibitor interferes with the development of specific cytotoxic T cells Figure 3 shows that addition of C1-inh down-regulated the development of allospecific cytotoxic activity in MLC in a Fig. 3 . Addition of C1-inh blocks the development of allo-specific cytotoxicity in a murine one-way, day 5 MLC. The presence of recombinant murine IL-2 (500 U/ml) partially bypasses the inhibition at 400 µg/ml of C1-inh. Each data point represents the mean specific 51 Cr release of four replicate cultures. Significant inhibition values (P Ͻ 0.05) were found for the addition of C1-inh to cultures at concentrations of 200-400 µg/ml (Wilcoxon rank sum test). Bars represent SD. dose-dependent manner. In addition, data in Fig. 3 show that addition of recombinant murine IL-2 to the MLC at high doses of C1-inh partly abrogated the suppressive effect of C1-inh (Fig. 3) 
C1-inh modulates cytokine production in MLC
The endogenous production of IL-2, IL-4, IL-10, IL-12 and IFN-γ was analyzed during the course of MLC in the presence Fig. 4 . Addition of C1-inh to a one-way MLC modulates the cytokine production of IFN-γ, IL-2, IL-4, IL-10 and IL-12 in a C1-inh dosedependent manner. Addition of C1-inh (u) 0 µg/ml; (j) 50 µg/ml; (m) 100 µg/ml; (s) 200 µg/ml; (d) 400 µg/ml. Experimental conditions as described in Methods.
or absence of C1-inh. As shown in Fig. 4 , the presence of C1-inh in the MLC induces a significant altered cytokine production in a dose-dependent manner. IFN-γ, IL-4, IL-10 and IL-12 were increased throughout the MLC, whereas the endogenous production of IL-2 was augmented only early in the culture (Fig. 4) . These findings led us to investigate the intracellular cytokines in the responder cell population of the MLC. As shown in Fig. 5(A) , cultures exposed to C1-inh contained 3 times as many IFN-γ/CD8 ϩ cells compared with cultures without C1-inh. The means of data from four separate experiments showed an increase of~100% of IFN-γ/CD8 ϩ cells (32.4 Ϯ 3.9 versus 16.4 Ϯ 4.5%, P Ͻ 0.05). No detectable IL-2, IL-4 and IL-10 was observed in CD8 ϩ T cells. Surprisingly, no difference in the fraction of IL-2/CD4 ϩ cells was observed between C1-inh exposed and control MLC respectively (Fig. 5B) . Likewise, no difference in the fraction of IL-4/CD4 ϩ and IL-10/CD ϩ cells was found between cultures with or without addition of C1-inh (data not shown).
Since IFN-γ is known to exert anti-proliferative effects, we tested whether the addition of a neutralizing anti-murine IFN-γ mAb could block the effect in MLC induced by C1-inh. As shown in Fig. 6 , the presence of anti-IFN-γ mAb could partly restore the proliferative response at day 5 in the MLC culture.
Discussion
This study shows that the presence of physiological levels of C1-inh in allogen-or mitogen-activated murine and human lymphocyte culture systems down-regulates the functional activity (Table 1 and 2, and Fig 1) . The effect of C1-inh affects both proliferation, generation of cytotoxic T lymphocytes (CTL) and the endogenous production of cytokines.
In our experiments we used purified human C1-inh known to act across distant species barriers (13, [15] [16] [17] . Thus, human as well as mouse C1-inh have previously been shown to inhibit the proteolytic activity of murine C1s complement (13). Likewise, in the present work both murine and human MLC and mitogen-responsive T cells were inhibited in the presence of human C1-inh.
Many different cell types (monocytes, macrophages and fibroblasts) have been reported to produce complement factors either spontaneously or in response to cytokines/IL (18) (19) (20) . It has thus been demonstrated that C1-inh is produced in response to IFN-γ by monocytes, although the biological significance of this is not known at present (19, 21) . IFN-γ, secreted by antigen-activated T h 1 cells, induces monocytes, fibroblasts, endothelial cells and hepatoma cells to synthesize many of the early complement components, as well as C1-inh (19, 21, 22) . The present observations may suggest that C1-inh and the early complement components can influence the afferent arm of the cellular immune responses. In this respect, C1-inh could function as a negative feedback regulator in the production of IL-2 and IL-4 from activated T cells.
Both IL-1 and IL-6 are produced during the early immune reaction. These cytokines are potent inducers of C-reactive protein (CRP) (23, 24) . Peripheral lymphocytes and macrophages can produce and bind CRP to their cell surface (25) , and CRP can react with the C1q complement component via the collagen-like region of C1q (26) . This reaction leads to activation of complement via the classical pathway without cell lysis (27) . We have previously shown that addition of intact β 2 m, but in particular the proteolytically processed form of β 2 m, desLys 58 β 2 m, can enhance development of cytotoxicity in MLC (3). Cleavage of MHC class I heavy chainassociated β 2 m which results in the formation of stimulatory desLys 58 β 2 m might therefore take place on the T cell surface by C1 complement bound to CRP. This idea is supported by the fact that β 2 m added to purified murine MLC responder cells, but not to the MLC supernatant, is proteolytically processed to the desLys 58 β 2 m form (3).
If C1 complement factors, bound to the cell via CRP, function as positive regulators of early T cell activation, the presence of C1-inh on the same cell surface (6) might counteract this regulation. We suggest that up-regulation of cell surface-expressed C1-inh might provide a mechanism for the prevention of autoreactivity, whereas C1-inh expressed on malignant cells (7-9) might prevent CTL-mediated antitumor reactivity. The more exact mechanisms by which the cleavage of β 2 m on T cells affects their activation and function is presently under investigation. It is tempting to speculate that the well known signal-transducing capability of T cell expressed MHC class I molecules (28-37) may be part of such a mechanism.
Since C1-inh affects the production of cytokines/IL, proliferation and generation of cytotoxic activity in MLC it is likely that endogenously produced C1-inh also modulates the immunological responses in the in vivo situation. In this context it is of interest to note that IFN-γ is capable of inducing the production of C1-inh in addition to a number of other complement components (19, 21) . Our finding that added C1-inh causes an increased production of IFN-γ may suggest that C1-inh and IFN-γ mutually up-regulate each other during the maturation of the immune response in vivo. This suggestion is further supported by our previous observation, mentioned above, showing that β 2 m cleaved by activated C1 complement induces an augmentation of the specific cytotoxic activity in a one-way MLC as well as to an increased endogenous IL-2 production early in the MLC (3). Other groups have also reported the importance of proteases in the afferent phase of the immune response, thus supporting our observation (38, 39) We hypothesize that β 2 m associated with the MHC class I heavy chain expressed on antigen-or mitogen-exposed T cells undergoes C1 complement-induced proteolytical cleavage (3) during the cellular activation process. This leads to a conformational change of the MHC class I heavy chain, which lowers the threshold level for cellular activation. The presence of exogenous C1-inh in the MLC blocks the macrophagederived C1s-mediated cleavage of β 2 m on the surface of the responding T cells and thereby interferes with optimal T cell activation. It should be noted that the concentration of C1-inh used in the present study equals levels of C1-inh present in normal serum, being in the range 100-600 µg/ml (40) .
In conclusion, the present results are the first to suggest that complement factors are of importance in antigen-specific and non-specific T cell activation. The physiological balance between cell-bound complement components and their inhibitors might thus be of importance for the tuning and subsequent outcome of an immune response.
